Avanos Medical Inc.
AVNS | NYSE
$24.99
+$0.01 (+0.04%)
Jul 24, 2026, 4:03 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 701.2M | 687.8M | 673.3M | 684.1M | 744.6M | 714.8M |
Cost of Revenue | 352.2M | 306.5M | 293.6M | 289.9M | 364.7M | 324.2M |
Gross Profit | 349M | 381.3M | 379.7M | 394.2M | 379.9M | 390.6M |
Operating Income | -61.6M | 40M | 65M | 41.9M | 86.8M | 70.9M |
Interest Income | 3.2M | 5.1M | 2.9M | 1.2M | 200K | 1.2M |
Pretax Income | -66.2M | -403.3M | -7.9M | 26.7M | 7.3M | -60.5M |
Net Income | -67.9M | -392.1M | -61.8M | 50.5M | 6.3M | -27.2M |
Selling & General & Admin | 218.3M | 315.1M | 287.5M | 323.1M | 260.8M | 284.8M |
Research & Development | 23.1M | 26.2M | 27.2M | 30.6M | 32.3M | 34.9M |
Other Expenses | 169.2M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 410.6M | 341.3M | 314.7M | 352.3M | 293.1M | 319.7M |
Interest Expense | 4M | 12.2M | 15M | 10M | 3.3M | 15.6M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 762.8M | 647.8M | 608.3M | 642.2M | 657.8M | 643.9M |
Income Tax Expense | 1.7M | -17M | 2M | 5.2M | 1M | -33.3M |
Shares Outstanding (Basic) | 46.4M | 46M | 46.6M | 46.9M | 48.1M | 47.8M |
Shares Outstanding (Diluted) | 46.4M | 46M | 46.6M | 47.3M | 48.6M | 47.8M |
EPS (Basic) | -1.46 | -8.53 | -1.33 | 1.08 | 0.13 | -0.57 |
EPS (Diluted) | -1.46 | -8.53 | -1.33 | 1.07 | 0.13 | -0.57 |
EBITDA | -33.2M | -345.6M | 50.6M | 77.8M | 48.9M | -2M |
EBIT | -62.2M | -391.1M | 7.1M | 36.7M | 10.6M | -44.9M |
Depreciation & Amortization | 29M | 45.5M | 43.5M | 41.1M | 38.3M | 42.9M |
Add to Watchlist
Select watchlists to add or remove AVNS